drugset
drugset / Trial / NCT04537351

The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause

NCT04537351 ↗

Phase 1 Completed 14 enrolled Cynata Therapeutics Limited Cerebral Palsy Alliance · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a pilot, multi-centre, open-label randomised controlled study to assess the early efficacy of intravenous (IV) administration of CYP-001 in adults admitted to an intensive care unit (ICU) with respiratory failure

Timeline

Start
2020-08-24
Primary completion
2022-04-27
Completion
2022-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject CYP-001 Cell therapy 2e+06 cells/kg Intravenous

Indications

COVID-19 adult acute respiratory distress syndrome